Do you find DFS as defined in POTOMAC a clinically meaningful endpoint for high-risk NMIBC, given that low-grade recurrences manageable with repeat TURBT would have qualified as events?

In my opinion, in patients with such an early stage of disease such as NMIBC, Disease-free survival (DFS) is a meaningful endpoint. Low-grade recurrences were excluded, and therefore, the clinically meaningful endpoints were preserved.

In POTOMAC, the primary endpoint was disease-free survival as measured by a high-risk NMIBC recurrence or progression to muscle-invasive disease. There was a secondary outcome of any disease-free survival that included the occurrence of low-grade recurrences, but that was a secondary outcome. The pr...